BRIEF published on 01/15/2026 at 11:50, 5 months 11 days ago Zürcher Kantonalbank's Disclosure on Avadel Pharmaceuticals Form 8.3 Irish Takeover Panel Securities Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/15/2026 at 11:45, 5 months 11 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank discloses ownership of 0.04% of Avadel Pharmaceuticals plc shares as of 14-Jan-2026, as per Form 8.3 filing with the Irish Takeover Panel Form 8.3 Irish Takeover Panel Ownership Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals Plc
BRIEF published on 01/14/2026 at 14:35, 5 months 12 days ago Zürcher Kantonalbank Discloses Position in Avadel Pharmaceuticals Ordinary Shares Disclosure Irish Takeover Panel Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/14/2026 at 14:30, 5 months 12 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank and subsidiaries disclosed 1.55% stake in Avadel Pharmaceuticals plc on 13th January 2026 Disclosure Irish Takeover Panel Stake Zürcher Kantonalbank Avadel Pharmaceuticals Plc
BRIEF published on 01/06/2026 at 12:50, 5 months 20 days ago Zürcher Kantonalbank Discloses Stake in Avadel Pharmaceuticals Form 8.3 Irish Takeover Panel Securities Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/06/2026 at 12:45, 5 months 20 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank and subsidiaries disclose a 0.04% interest in Avadel Pharmaceuticals plc. Details of open stock-settled derivatives positions provided Disclosure Irish Takeover Panel Stock-settled Derivatives Zürcher Kantonalbank Avadel Pharmaceuticals Plc
BRIEF published on 01/05/2026 at 20:35, 5 months 21 days ago Zürcher Kantonalbank Discloses Position in Avadel Pharmaceuticals Form 8.3 Irish Takeover Panel Securities Holding Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/05/2026 at 20:30, 5 months 21 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank and subsidiaries disclosed a 1.02% interest in Avadel Pharmaceuticals plc shares on 2nd January 2026 Shares Disclosure Interests Zürcher Kantonalbank Avadel Pharmaceuticals Plc
BRIEF published on 01/05/2026 at 17:05, 5 months 21 days ago Zürcher Kantonalbank Discloses Position in Avadel Pharmaceuticals Form 8.3 Irish Takeover Panel Securities Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals
PRESS RELEASE published on 01/05/2026 at 17:00, 5 months 21 days ago Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc Zürcher Kantonalbank discloses 1.02% position in Avadel Pharmaceuticals plc as of 31st December 2025 following dealing activities Position Disclosure Zürcher Kantonalbank Avadel Pharmaceuticals Plc 1.02% Dealing Activities
Published on 06/26/2026 at 23:00, 1 minute ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 11 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 46 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/26/2026 at 14:05, 8 hours 56 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 19:50, 3 hours 10 minutes ago Name Change Completed for C Capital's Swiss Listed Entity, Ticker Symbol CCAP Goes Live
Published on 06/26/2026 at 19:10, 3 hours 50 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/26/2026 at 18:04, 4 hours 56 minutes ago Turkiye Garanti Bankasi A.S.: Bond, subordinated debts, that can be included in the equity calculation debt instrument issuance CMB Application
Published on 06/26/2026 at 18:00, 5 hours ago PSP Swiss Property has sold the Richtipark in Wallisellen. The EBITDA guidance for the 2026 financial year has been increased.
Published on 06/26/2026 at 18:00, 5 hours ago VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M
Published on 06/26/2026 at 07:00, 16 hours 1 minute ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 07:30, 1 day 15 hours ago Gimv signs an agreement to acquire Groupe Cap Vert, France’s leading multi-specialist provider of tree and vegetation critical management services, from Ambienta.
